Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02023697
Registration number
NCT02023697
Ethics application status
Date submitted
24/12/2013
Date registered
30/12/2013
Date last updated
12/07/2019
Titles & IDs
Public title
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Query!
Scientific title
A Three Arm Randomized, Open-label Phase II Study of Radium-223 Dichloride 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) Versus 80 kBq/kg (88 kBq/kg After Implementation of NIST Update), and Versus 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) in an Extended Dosing Schedule in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone
Query!
Secondary ID [1]
0
0
2013-003118-42
Query!
Secondary ID [2]
0
0
16507
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostatic Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Radium-223 dichloride (Xofigo, BAY88-8223)
Experimental: Radium-223 dichloride (Standard dose) - One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
Experimental: Radium-223 dichloride (High dose) - One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update).
Experimental: Radium-223 dichloride (Extended standard dose) - One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
Treatment: Drugs: Radium-223 dichloride (Xofigo, BAY88-8223)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard Dose
Query!
Assessment method [1]
0
0
Symptomatic skeletal event (SSE) free survival is based on the following events: the use of external beam radiotherapy (EBRT) to relieve skeletal symptoms; the occurrence of new symptomatic pathological bone fractures (vertebral or nonvertebral); the occurrence of spinal cord compression; a tumor related orthopedic surgical intervention, and death. In this evaluation - comparison 1, SSE-FS following randomization is defined in ITT participants as the time from randomization to an SSE or death, whichever occurs first.
Query!
Timepoint [1]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Primary outcome [2]
0
0
Symptomatic Skeletal Event-Free Survival - High Dose vs. Standard Dose
Query!
Assessment method [2]
0
0
In this evaluation - comparison 1, SSE-FS following randomization is defined in ITT participants as the time from randomization to an SSE or death, whichever occurs first.
Query!
Timepoint [2]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Primary outcome [3]
0
0
Number of Participants With an Event Defining SSE Free Survival - Extended Dose vs. Standard Dose
Query!
Assessment method [3]
0
0
Symptomatic skeletal event (SSE) free survival is based on the following events: the use of external beam radiotherapy (EBRT) to relieve skeletal symptoms; the occurrence of new symptomatic pathological bone fractures (vertebral or nonvertebral); the occurrence of spinal cord compression; a tumor related orthopedic surgical intervention, and death. In this evaluation - Comparison 2, SSE-FS from 6th dose is defined in W24 participants as the time from Week 24 baseline (the 6th dose date) to an SSE or death, whichever occurs first.
Query!
Timepoint [3]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Primary outcome [4]
0
0
Symptomatic Skeletal Event-Free Survival - Extended Dose vs. Standard Dose
Query!
Assessment method [4]
0
0
In this evaluation - Comparison 2, SSE-FS from 6th dose is defined in W24 participants as the time from Week 24 baseline (the 6th dose date) to an SSE or death, whichever occurs first.
Query!
Timepoint [4]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Primary outcome [5]
0
0
Number of Participants With an Event Defining SSE Free Survival - Three Dose Groups As Randomized
Query!
Assessment method [5]
0
0
Symptomatic skeletal event (SSE) free survival is based on the following events: the use of external beam radiotherapy (EBRT) to relieve skeletal symptoms; the occurrence of new symptomatic pathological bone fractures (vertebral or nonvertebral); the occurrence of spinal cord compression; a tumor related orthopedic surgical intervention, and death.
Query!
Timepoint [5]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Primary outcome [6]
0
0
Symptomatic Skeletal Event Free Survival - Three Dose Groups As Randomized
Query!
Assessment method [6]
0
0
Symptomatic skeletal event (SSE) is defined as follows: The use of external beam radiotherapy (EBRT) to relieve skeletal symptoms; The occurrence of new symptomatic pathological bone fractures (vertebral or nonvertebral); The occurrence of spinal cord compression; A tumor related orthopedic surgical intervention.
Query!
Timepoint [6]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [1]
0
0
Number of Participants With an Overall Survival Event - High Dose vs. Standard Dose
Query!
Assessment method [1]
0
0
Overall survival was defined as the time in days from the applicable start date to the date of death due to any cause. Participants who were still alive or who were lost to survival follow-up as of database cut-off date were to be censored at the last known alive date on or prior to database cut-off date.
Query!
Timepoint [1]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [2]
0
0
Overall Survival - High Dose vs. Standard Dose
Query!
Assessment method [2]
0
0
Overall survival was defined as the time in days from the applicable start date to the date of death due to any cause. Participants who were still alive or who were lost to survival follow-up as of database cut-off date were to be censored at the last known alive date on or prior to database cut-off date.
Query!
Timepoint [2]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [3]
0
0
Number of Participants With an Overall Survival Event - Extended Dose vs. Standard Dose
Query!
Assessment method [3]
0
0
Overall survival was defined as the time in days from the applicable start date to the date of death due to any cause. Participants who were still alive or who were lost to survival follow-up as of database cut-off date were to be censored at the last known alive date on or prior to database cut-off date.
Query!
Timepoint [3]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [4]
0
0
Overall Survival - Extended Dose vs. Standard Dose
Query!
Assessment method [4]
0
0
Overall survival was defined as the time in days from the applicable start date to the date of death due to any cause. Participants who were still alive or who were lost to survival follow-up as of database cut-off date were to be censored at the last known alive date on or prior to database cut-off date.
Query!
Timepoint [4]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [5]
0
0
Number of Participants With an Overall Survival - Three Dose Groups As Randomized
Query!
Assessment method [5]
0
0
Overall survival was defined as the time in days from the applicable start date to the date of death due to any cause. Participants who were still alive or who were lost to survival follow-up as of database cut-off date were to be censored at the last known alive date on or prior to database cut-off date.
Query!
Timepoint [5]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [6]
0
0
Overall Survival Event - Three Dose Groups as Randomized
Query!
Assessment method [6]
0
0
Overall survival was defined as the time in days from the applicable start date to the date of death due to any cause. Participants who were still alive or who were lost to survival follow-up as of database cut-off date were to be censored at the last known alive date on or prior to database cut-off date.
Query!
Timepoint [6]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [7]
0
0
Number of Participants With First Symptomatic Skeletal Event - High Dose vs. Standard Dose
Query!
Assessment method [7]
0
0
Symptomatic skeletal event (SSE) is defined as follows: The use of external beam radiotherapy (EBRT) to relieve skeletal symptoms; The occurrence of new symptomatic pathological bone fractures (vertebral or nonvertebral); The occurrence of spinal cord compression; A tumor related orthopedic surgical intervention.
Query!
Timepoint [7]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [8]
0
0
Time to First Symptomatic Skeletal Event - High Dose vs. Standard Dose
Query!
Assessment method [8]
0
0
Time to first SSE is defined as the time in days from the applicable start date to the first SSE on or following the start date.
Query!
Timepoint [8]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [9]
0
0
Number of Participants With First Symptomatic Skeletal Event - Extended Dose vs. Standard Dose
Query!
Assessment method [9]
0
0
Symptomatic skeletal event (SSE) is defined as follows: The use of external beam radiotherapy (EBRT) to relieve skeletal symptoms; The occurrence of new symptomatic pathological bone fractures (vertebral or nonvertebral); The occurrence of spinal cord compression; A tumor related orthopedic surgical intervention.
Query!
Timepoint [9]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [10]
0
0
Time to First Symptomatic Skeletal Event - Extended Dose vs. Standard Dose
Query!
Assessment method [10]
0
0
Time to first SSE is defined as the time in days from the applicable start date to the first SSE on or following the start date.
Query!
Timepoint [10]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [11]
0
0
Number of Participants With First Symptomatic Skeletal Event - Three Dose Groups as Randomized
Query!
Assessment method [11]
0
0
Symptomatic skeletal event (SSE) is defined as follows: The use of external beam radiotherapy (EBRT) to relieve skeletal symptoms; The occurrence of new symptomatic pathological bone fractures (vertebral or nonvertebral); The occurrence of spinal cord compression; A tumor related orthopedic surgical intervention.
Query!
Timepoint [11]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [12]
0
0
Time to First Symptomatic Skeletal Event - Three Dose Groups as Randomized
Query!
Assessment method [12]
0
0
Time to first SSE is defined as the time in days from the applicable start date to the first SSE on or following the start date.
Query!
Timepoint [12]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [13]
0
0
Number of Participants With a Radiological Progression Event-Free - High Dose vs. Standard Dose
Query!
Assessment method [13]
0
0
Radiological progression of soft tissue disease is determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on Magnetic resonance imaging (MRI) or computed tomography (CT) scans. Radiological progression of osseous disease is determined according to adapted PCWG2 criteria based on whole body technetium-99 bone scans. Radiological bone progression is determined if at least one of the following criteria is met: The first bone scan with =2 new lesions compared to baseline is observed <12 weeks from randomization and is confirmed by a second bone scan taken =6 weeks later showing =2 additional new lesions (a total of =4 new lesions compared to baseline); or The first bone scan with =2 new lesions compared to baseline is observed =12 weeks from randomization and the new lesions are verified on the next bone scan =6 weeks later (a total of =2 new lesions compared to baseline).
Query!
Timepoint [13]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [14]
0
0
Radiological Progression Free Survival - High Dose vs. Standard Dose
Query!
Assessment method [14]
0
0
Radiological progression free survival is defined as the time in days from the applicable start date to the date of subsequent radiological disease progression or death from any cause (if death occurs before such progression). Participants not experiencing death or radiological disease progression as of database cut-off were censored at the last radiological disease progression assessment.
Query!
Timepoint [14]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [15]
0
0
Number of Participants With a Radiological Progression Event-Free - Extended Dose vs. Standard Dose
Query!
Assessment method [15]
0
0
Radiological progression of soft tissue disease is determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on Magnetic resonance imaging (MRI) or Computed tomography (CT) scans. Radiological progression of osseous disease is determined according to adapted PCWG2 criteria based on whole body technetium-99 bone scans.
Query!
Timepoint [15]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [16]
0
0
Radiological Progression Free Survival - Extended Dose vs. Standard Dose
Query!
Assessment method [16]
0
0
Radiological progression free survival is defined as the time in days from the applicable start date to the date of subsequent radiological disease progression or death from any cause (if death occurs before such progression). Participants not experiencing death or radiological disease progression as of database cut-off were censored at the last radiological disease progression assessment.
Query!
Timepoint [16]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [17]
0
0
Number of Participants With a Radiological Progression Event-Free - Three Dose Groups as Randomized
Query!
Assessment method [17]
0
0
Radiological progression of soft tissue disease is determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on Magnetic resonance imaging (MRI) or Computed tomography (CT) scans. Radiological progression of osseous disease is determined according to adapted Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria based on whole body technetium-99 bone scans.
Query!
Timepoint [17]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [18]
0
0
Radiological Progression Free Survival - Three Dose Groups as Randomized
Query!
Assessment method [18]
0
0
Radiological progression free survival is defined as the time in days from the applicable start date to the date of subsequent radiological disease progression or death from any cause (if death occurs before such progression). Participants not experiencing death or radiological disease progression as of database cut-off were censored at the last radiological disease progression assessment.
Query!
Timepoint [18]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [19]
0
0
Number of Participants With a Radiological Progression Event - High Dose vs. Standard Dose
Query!
Assessment method [19]
0
0
Radiological progression of soft tissue disease is determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on Magnetic resonance imaging (MRI) or Computed tomography (CT) scans. Radiological progression of osseous disease is determined according to adapted Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria based on whole body technetium-99 bone scans.
Query!
Timepoint [19]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [20]
0
0
Time to Radiological Progression - High Dose vs. Standard Dose
Query!
Assessment method [20]
0
0
Time to radiological progression is defined as the time in days from the applicable start date to the date of subsequent radiological progression. Participants without radiological progression as of database cut-off date, whether or not surviving, were censored at the last radiological progression assessment.
Query!
Timepoint [20]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [21]
0
0
Number of Participants With a Radiological Progression Event - Extended Dose vs. Standard Dose
Query!
Assessment method [21]
0
0
Radiological progression free survival is defined as the time in days from the applicable start date to the date of subsequent radiological disease progression or death from any cause (if death occurs before such progression). Participants not experiencing death or radiological disease progression as of database cut-off were censored at the last radiological disease progression assessment.
Query!
Timepoint [21]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [22]
0
0
Time to Radiological Progression - Extended Dose vs. Standard Dose
Query!
Assessment method [22]
0
0
Time to radiological progression is defined as the time in days from the applicable start date to the date of subsequent radiological progression. Participants without radiological progression as of database cut-off date, whether or not surviving, were censored at the last radiological progression assessment.
Query!
Timepoint [22]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [23]
0
0
Number of Participants With a Radiological Progression Event - Three Dose Groups as Randomized
Query!
Assessment method [23]
0
0
Radiological progression free survival is defined as the time in days from the applicable start date to the date of subsequent radiological disease progression or death from any cause (if death occurs before such progression). Participants not experiencing death or radiological disease progression as of database cut-off were censored at the last radiological disease progression assessment.
Query!
Timepoint [23]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [24]
0
0
Time to Radiological Progression - Three Dose Groups as Randomized
Query!
Assessment method [24]
0
0
Time to radiological progression is defined as the time in days from the applicable start date to the date of subsequent radiological progression. Participants without radiological progression as of database cut-off date, whether or not surviving, were censored at the last radiological progression assessment.
Query!
Timepoint [24]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [25]
0
0
Timepoint Pain Improvement Rate - Three Dose Groups as Randomized
Query!
Assessment method [25]
0
0
Timepoint pain improvement rate is defined as the proportion of participants with a 30% and 2-point decrease in Worst pain score (WPS) from baseline over 2 consecutive assessment periods conducted at least 4 weeks apart among participants with a WPS score = 4 at baseline.
Query!
Timepoint [25]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [26]
0
0
Timepoint Pain Improvement Rate - Extended Dose vs. Standard Dose
Query!
Assessment method [26]
0
0
Timepoint pain improvement rate is defined as the proportion of participants with a 30% and 2-point decrease in Worst pain score (WPS) from baseline over 2 consecutive assessment periods conducted at least 4 weeks apart among participants with a WPS score = 4 at baseline.
Query!
Timepoint [26]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [27]
0
0
Number of Participants With a Pain Progression Event - High Dose vs. Standard Dose
Query!
Assessment method [27]
0
0
Participants were divided in 3 groups according to baseline pain evaluation: asymptomatic subjects (WPS 0 to < 1 at baseline); mildly symptomatic subjects (WPS 1-3 at baseline); and symptomatic subjects with WPS > 3 and = 7 at baseline). Pain progression was defined as the occurrence of a pain increase of 2 or more points in the average (i.e., average of 7-day assessments) "worst pain in 24 hours" score from baseline observed at 2 consecutive evaluations = 4 weeks apart. Participants with insufficient applicable baseline assessments or without adequate post-baseline assessments were to be censored at the applicable baseline date.
Query!
Timepoint [27]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [28]
0
0
Time to Pain Progression - High Dose vs. Standard Dose
Query!
Assessment method [28]
0
0
The time to pain progression is defined for each applicable baseline for applicable participants as the time (in days) from the respective baseline until occurrence of the first post-baseline pain progression event.
Query!
Timepoint [28]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [29]
0
0
Number of Participants With a Pain Progression Event - Extended Dose vs. Standard Dose
Query!
Assessment method [29]
0
0
Pain progression is defined for each baseline in participants evaluable for pain progression at the applicable baseline, i.e., participants with a WPS of = 7 at the respective baseline assessment.
Query!
Timepoint [29]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [30]
0
0
Time to Pain Progression - Extended Dose vs. Standard Dose
Query!
Assessment method [30]
0
0
The time to pain progression is defined for each applicable baseline for applicable participants as the time (in days) from the respective baseline until occurrence of the first post-baseline pain progression event.
Query!
Timepoint [30]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [31]
0
0
Number of Participants With a Pain Progression Event - Three Dose Groups as Randomized
Query!
Assessment method [31]
0
0
Pain progression is defined for each baseline in participants evaluable for pain progression at the applicable baseline, i.e., participants with a WPS of = 7 at the respective baseline assessment.
Query!
Timepoint [31]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [32]
0
0
Time to Pain Progression - Three Dose Groups as Randomized
Query!
Assessment method [32]
0
0
The time to pain progression is defined for each applicable baseline for applicable participants as the time (in days) from the respective baseline until occurrence of the first post-baseline pain progression event.
Query!
Timepoint [32]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Secondary outcome [33]
0
0
Number of Participants With Treatment-Emergent Adverse Events
Query!
Assessment method [33]
0
0
Treatment-emergent adverse events are events starting or worsening from the initiation of treatment until 30 days after the last administration of radium-223 dichloride. The intensity of an AE is classified according to the grades specified by the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE).
Query!
Timepoint [33]
0
0
From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
Query!
Eligibility
Key inclusion criteria
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Castration-resistant disease defined as:
- Serum testosterone level: = 50 ng/dL (1.7 nmol/L)
- Bilateral orchiectomy or maintenance on androgen ablation therapy with
luteinizing-hormone-releasing hormone (LHRH) agonist or antagonist, or
polyestradiol phosphate
- Serum PSA (Prostate specific antigen) progression defined as 2 subsequent
increases in PSA over a previous reference value (a minimum of 2 ng/mL [µg/L]) OR
- Radiographic evidence of disease progression in bone (according to Prostate
Cancer Clinical Trials Working Group 2 [PCWG2] criteria) with or without PSA
progression
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2. In case of
ECOG PS 2, the PS has to be due to metastatic prostate cancer to the bone.
- Two or more skeletal metastases (= 2 hot spots) on bone scintigraphy within 8 weeks of
randomization
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of visceral metastasis, or visceral metastases
- Lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter
- Central nervous system (CNS) metastases
- Treatment with cytotoxic chemotherapy for prostate cancer within the previous 4 weeks
prior to randomization, or planned treatment with cytotoxic chemotherapy agents for
prostate cancer during the treatment period or follow-up
- Chronic conditions associated with non-malignant abnormal bone growth (e.g. confirmed
Paget's disease of bone)
- Prior treatment with radium-223 dichloride
- Prior systemic radiotherapy and hemibody external radiotherapy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/03/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
9/08/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
391
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Melbourne
Query!
Recruitment hospital [3]
0
0
- Box Hill
Query!
Recruitment hospital [4]
0
0
- Darlinghurst
Query!
Recruitment hospital [5]
0
0
- Westmead
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3052 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [5]
0
0
2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nebraska
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oregon
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Rio Grande Do Sul
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Sao Paulo
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Ontario
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Quebec
Query!
Country [15]
0
0
Chile
Query!
State/province [15]
0
0
Santiago
Query!
Country [16]
0
0
Czechia
Query!
State/province [16]
0
0
Chomutov
Query!
Country [17]
0
0
Czechia
Query!
State/province [17]
0
0
Praha 5
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Nantes
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Vandoeuvre les Nancy
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Villejuif Cedex
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Baden-Württemberg
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Bayern
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Sachsen
Query!
Country [24]
0
0
Israel
Query!
State/province [24]
0
0
Beer Sheva
Query!
Country [25]
0
0
Israel
Query!
State/province [25]
0
0
Haifa
Query!
Country [26]
0
0
Israel
Query!
State/province [26]
0
0
Jerusalem
Query!
Country [27]
0
0
Israel
Query!
State/province [27]
0
0
Kfar Saba
Query!
Country [28]
0
0
Israel
Query!
State/province [28]
0
0
Petah Tikva
Query!
Country [29]
0
0
Israel
Query!
State/province [29]
0
0
Ramat Gan
Query!
Country [30]
0
0
Italy
Query!
State/province [30]
0
0
Emilia-Romagna
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Lazio
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Piemonte
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Toscana
Query!
Country [34]
0
0
Korea, Republic of
Query!
State/province [34]
0
0
Busan Gwang''yeogsi
Query!
Country [35]
0
0
Korea, Republic of
Query!
State/province [35]
0
0
Seoul Teugbyeolsi
Query!
Country [36]
0
0
Korea, Republic of
Query!
State/province [36]
0
0
Seoul
Query!
Country [37]
0
0
Spain
Query!
State/province [37]
0
0
Barcelona
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Illes Baleares
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Madrid
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Pamplona
Query!
Country [41]
0
0
Sweden
Query!
State/province [41]
0
0
Göteborg
Query!
Country [42]
0
0
Sweden
Query!
State/province [42]
0
0
Karlstad
Query!
Country [43]
0
0
Sweden
Query!
State/province [43]
0
0
Sundsvalls
Query!
Country [44]
0
0
Sweden
Query!
State/province [44]
0
0
Umeå
Query!
Country [45]
0
0
Taiwan
Query!
State/province [45]
0
0
Taipei
Query!
Country [46]
0
0
Taiwan
Query!
State/province [46]
0
0
Taoyuan
Query!
Country [47]
0
0
Taiwan
Query!
State/province [47]
0
0
Kaohsiung
Query!
Country [48]
0
0
Taiwan
Query!
State/province [48]
0
0
Taichung
Query!
Country [49]
0
0
United Kingdom
Query!
State/province [49]
0
0
Merseyside
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Somerset
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
Northwood
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will assess different doses and regimens of radium-223 dichloride on the incidence
of symptomatic skeletal events. Eligible subjects must have castration resistant prostate
cancer with 2 or more skeletal metastases documented within 8 weeks of randomization.
Subjects will be randomized to one of 3 treatment arms in a 1:1:1 fashion: a standard regimen
of radium-223 dichloride of 50 kBq/kg (55 kBq/kg after implementation of NIST update)
injections every month for 6 months, a high dose regimen of 80 kBq/kg (88 kBq/kg after
implementation of NIST update)injections every month for 6 months or an extended duration
regimen of 50 kBq/kg (55 kBq/kg after implementation of NIST update) injections every month
for 12 months. Following the treatment phase, subjects will be followed up every 12 weeks for
a minimum of 2 years, at which point they will enter a long term follow-up period during
which they are seen every 6 months for up to 7 years after the last dose of radium
dichloride. Symptomatic skeletal event and safety endpoints will be assessed at each clinic
visit. Pain and analgesic use data will be collected every 4 weeks through Week 48.
Additionally, radiological assessments including MRI/CT of the abdomen and pelvis and chest
CT, as well as technetium-99 bone scans will be performed at Weeks 8, 16, and 24 and continue
every 12 weeks thereafter until disease progression is documented in either the bone or in
soft tissue. Radiological imaging will be evaluated by blinded central review.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02023697
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02023697
Download to PDF